The principal findings of this study are that (1) targeting podoplanin in vivo limits acute lung inflammation, improving animal welfare during IT-LPS, and (2) podoplanin expressed on in vitro-generated inflammatory alveolar macrophages regulates their cytokine/chemokine secretion. This evidence concerns the gene PDPN and inflammatory response.